TFRC and breast cancer: Although the amount of Eve encapsulated in HFn nanocages is lower than observed with other drugs [13,20], its formulation in HFn nanocages increases the drug’s ability to inhibit BC cell proliferation thanks to its increased cellular uptake, probably due to TfR1-mediated internalization [13].